Rockwell Medical Inc (RMTI)
1.52
+0.03
(+2.01%)
USD |
NASDAQ |
Apr 25, 12:50
Rockwell Medical Enterprise Value: 41.31M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 41.31M |
| April 23, 2024 | 42.48M |
| April 22, 2024 | 42.04M |
| April 19, 2024 | 40.14M |
| April 18, 2024 | 41.02M |
| April 17, 2024 | 41.02M |
| April 16, 2024 | 41.31M |
| April 15, 2024 | 42.34M |
| April 12, 2024 | 44.54M |
| April 11, 2024 | 45.12M |
| April 10, 2024 | 43.95M |
| April 09, 2024 | 45.12M |
| April 08, 2024 | 45.12M |
| April 05, 2024 | 46.00M |
| April 04, 2024 | 47.18M |
| April 03, 2024 | 45.42M |
| April 02, 2024 | 46.30M |
| April 01, 2024 | 47.47M |
| March 28, 2024 | 46.30M |
| March 27, 2024 | 45.71M |
| March 26, 2024 | 46.00M |
| March 25, 2024 | 45.12M |
| March 22, 2024 | 47.76M |
| March 21, 2024 | 42.19M |
| March 20, 2024 | 45.67M |
| Date | Value |
|---|---|
| March 19, 2024 | 38.68M |
| March 18, 2024 | 38.09M |
| March 15, 2024 | 38.38M |
| March 14, 2024 | 38.09M |
| March 13, 2024 | 40.13M |
| March 12, 2024 | 39.55M |
| March 11, 2024 | 42.46M |
| March 08, 2024 | 41.88M |
| March 07, 2024 | 42.17M |
| March 06, 2024 | 41.30M |
| March 05, 2024 | 40.72M |
| March 04, 2024 | 40.42M |
| March 01, 2024 | 43.05M |
| February 29, 2024 | 38.68M |
| February 28, 2024 | 37.22M |
| February 27, 2024 | 37.51M |
| February 26, 2024 | 37.51M |
| February 23, 2024 | 34.31M |
| February 22, 2024 | 35.18M |
| February 21, 2024 | 36.35M |
| February 20, 2024 | 36.64M |
| February 16, 2024 | 36.93M |
| February 15, 2024 | 38.09M |
| February 14, 2024 | 35.18M |
| February 13, 2024 | 35.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-3.068M
Minimum
Nov 09 2022
300.33M
Maximum
May 08 2019
68.31M
Average
51.40M
Median
Jun 16 2023
Enterprise Value Benchmarks
| Cyclacel Pharmaceuticals Inc | -0.346M |
| Oragenics Inc | 3.306M |
| Alpine Immune Sciences Inc | 3.905B |
| Corvus Pharmaceuticals Inc | 46.90M |
| MAIA Biotechnology Inc | 48.21M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.512M |
| Revenue (Quarterly) | 22.09M |
| Total Expenses (Quarterly) | 22.64M |
| EPS Diluted (Quarterly) | -0.05 |
| Gross Profit Margin (Quarterly) | 12.99% |
| Profit Margin (Quarterly) | -6.84% |
| Earnings Yield | -26.32% |
| Normalized Earnings Yield | -27.07 |